CDSCO Guidelines

Central Drugs Standard Control Organisation - The national regulatory authority for pharmaceuticals, cosmetics, and medical devices in India.

90

Working Days CT

Zone IVb

Stability Zone

ACTD

Dossier Format

SEC

Expert Committee

Drug Approval Pathways

New Drug Approval

12-18 months

For drugs not previously approved in India. Requires complete safety and efficacy data including local clinical trials.

Key Requirements:

  • Global clinical trial data
  • Indian bridging/pivotal studies
  • Stability data under Zone IVb conditions
  • CMC data per ACTD format

Generic Drug Approval

6-12 months

For drugs with established safety profile. Bioequivalence based approval with reference to innovator product.

Key Requirements:

  • Bioequivalence study in Indian subjects
  • 3 exhibit batches
  • 6-month accelerated stability
  • DMF for API

Import Registration

6-9 months

For marketing of drugs manufactured outside India. Requires registration certificate from country of origin.

Key Requirements:

  • Free Sale Certificate from CoO
  • GMP certificate
  • Product dossier in CTD format
  • Authorized Indian agent

Clinical Trial Approval

90 working days

Permission to conduct clinical trials in India under New Drugs and Clinical Trials Rules 2019.

Key Requirements:

  • Protocol and IB approval
  • Ethics Committee approval
  • Insurance/compensation provisions
  • Investigator credentials

Submission Process

1

Pre-Submission Consultation

Optional meeting with CDSCO to discuss development plans and requirements

2

Application Preparation

Compile dossier per ACTD/CTD format with all required documents

3

SUGAM Portal Submission

Online submission through CDSCO SUGAM portal with fee payment

4

Scrutiny & Evaluation

CDSCO technical review and Subject Expert Committee (SEC) evaluation

5

Site Inspection

Manufacturing facility inspection by CDSCO inspectors

6

Approval/License

Grant of approval or import license for marketing

Reference Documents

New Drugs and Clinical Trials Rules, 2019

Comprehensive rules governing clinical trials and new drug approvals

Document Viewer

PDF documents will be displayed here. Upload or link your regulatory documents to view them directly in the browser.

CDSCO Guidance on Bioequivalence Studies

Guidelines for conducting BE studies in India

Document Viewer

PDF documents will be displayed here. Upload or link your regulatory documents to view them directly in the browser.

Key Regulations

Drugs and Cosmetics Act, 1940

Primary legislation governing drugs in India

Drugs and Cosmetics Rules, 1945

Implementing rules under the Act

New Drugs and Clinical Trials Rules, 2019

Comprehensive CT and new drug regulations

Schedule Y

Requirements for new drug approval

Schedule M

GMP requirements for manufacturing

Schedule H/H1/X

Prescription drug classifications

Zone IVb Stability

Long-term30°C ± 2°C / 65% RH ± 5%
Intermediate30°C ± 2°C / 65% RH ± 5%
Accelerated40°C ± 2°C / 75% RH ± 5%
Duration (Long-term)Minimum 12 months at submission
Duration (Accelerated)6 months

SUGAM Portal

All applications must be submitted online through the CDSCO SUGAM portal.

Online application tracking
Digital fee payment
Document upload system